{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.41","upperLimit":"1.51","value":"1.48"},{"groupId":"OG001","lowerLimit":"1.41","upperLimit":"1.54","value":"1.48"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"description":"Time to response was defined as the time from first dose to first radiographic evidence of response.","dispersionType":"95% Confidence Interval","groups":[{"description":"Encorafenib + binimetinib + cetuximab. Encorafenib: Orally, once daily. Binimetinib: Orally, twice daily. Cetuximab: Standard of care.","id":"OG000","title":"Phase 3: Triplet Arm"},{"description":"Encorafenib + cetuximab. Encorafenib: Orally, once daily. Cetuximab: Standard of care.","id":"OG001","title":"Phase 3:Doublet Arm"}],"paramType":"MEDIAN","populationDescription":"The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 participants. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From first dose to first radiographic evidence of response (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm)","title":"(Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per Investigator","type":"SECONDARY","unitOfMeasure":"Months"}